What DNA Testing Companies’ Terrifying Privacy Policies Actually Mean
By Kristen V. Brown,
Gizmodo
| 10. 18. 2017
You probably wouldn’t hand out your social security number without having a pretty good idea of how that information was going to be used, right? That would be dumb. It’s extremely sensitive information. And yet, the consumer genetic testing market is booming thanks to people readily giving up another piece of their identity: their genetic code.
Ever-cheaper DNA sequencing technology has allowed genetic testing to become far more than a tool for doctors. Genetic testing has become entertainment, with companies offering tests that provide insight into ancestry, athletic ability, sleep habits and much more. The consumer genetic testing market was valued at $70 million in 2015, but estimates expect it to expand to $340 million by 2022.
When you spit in a test tube in in hopes of finding out about your ancestry or health or that perfect, genetically optimized bottle of wine, you’re giving companies access to some very intimate details about what makes you, you. Your genes don’t determine everything about who you are, but they do contain revealing information about your health, relationships, ...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...